This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
17
DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Research site
New York, New York, United States
Research site
Albury, New South Wales, Australia
Research site
Ballarat, Victoria, Australia
Research site
Melbourne, Victoria, Australia
Research site
Part A: Incidence of adverse events
Time frame: 30 days after the last dose, assessed up to 2 years
Part B: Objective Response Rate assessed by investigators
Time frame: assessed up to 2 years
Part A: Objective Response Rate assessed by investigators
Time frame: assessed up to 2 years
Part A: Plasma and CSF concentration of DZD8586
Time frame: through discontinuation of treatment up to 10 weeks
Part B: Duration of Response assessed by investigators
Time frame: from date of first documented response until the date of documented progression, assessed up to 2 years
Part B: Incidence of adverse events
Time frame: 30 days after the last dose, assessed up to 2 years
Part B: Plasma and CSF concentration of DZD8586
Time frame: through discontinuation of treatment, assessed up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Perth, Western Australia, Australia